[1] 袁小林,张秀林,赵红,等.肝癌患者血清肿瘤标记物联合检测结果的判别分析[J].临床肿瘤学杂志,2000,7(5):331-3.Yuan XL,Zhang XL,Zhao H,et al.Discrimination analyses of the results of circulating tumor markers simultaneous determination in liver cancer patients [J].Chin Ciin Oncol,2000,7(5):331-3. [2] 徐白董,田嘉禾,何义杰,等.FDG-PET在肝脏恶性肿瘤诊断中的应用[J].中华核医学杂志,2002,22(3):139-40.Xu BX,TianJH,He YJ,et al.Evaluation of liver tumor with 18F-FDG PET[J].ChinJNucl Med,2002,22(3):139-40. [3] 刘新兰,王宁菊.原发性肝癌栓塞化疗后血清AFP浓度与疗效关系的探讨[J].广西医学,2003,25(1):7-8..Liu XL,Wang NJ.The relationship between serum AFP concentration and curative effect in primary hepatic carcinoma after TACE[J].Guangxi MedJ,2003,25(1):7-8. [4] 汤钊猷.现代肿瘤学[M].上海医科大学出版社,1993.562-3. [5] 魏东,邓爱文,牟成惠.ICA、RIA和ELISA法测定甲胎蛋白的比较[J].第一军医大学学报,2001,21(6):459-60.Wei D,Deng AW,Mu CH.Determination of serurn α-fetoprotein by ICA,RIA and ELISA:a comparative study [J].JFirst Mil Med Univ/Di YiJun Yi Da Xue Xue Bao,2001,21(6):459-60. [6] 王易化,杨静华,何开路,等.甲胎蛋白对肝癌细胞生长的影响l:人AFP对小鼠H22腹水型肝细胞肝癌RNA合成的促进作用[J].中国肿瘤临床(ChinJClinOnco1),1989,16(5):293-5. [7] 高蕾,白岚,南清振,等.肝癌患者血清和腹水可溶性肿瘤坏死因子受体p55的测定[J].第一军医大学学报,2002,22(7):641-3.Gao L,Bai L,Nan QZ,et al.Detection of soluble tumor necrosis factor -p55 levels in the serum and ascitic fluid of patients with hepatocellular carcinoma[J].JFirst Mil Med Univ/Di YiJun Yi Da Xue Xue Bao,2002,22(7):641-3. [8] Patz EF,Lowe VJ,HoffmanJM,et al.Focal pulmonary abnormalities:evaluation with 18F-fluorodexy glucose PET scanning [J].Radiology,1993,188(45):487-90. [9] Sazon DA,Santiago SM,Soohoo GW,et al.Fluowdexyglucose positron emission tomography in the detection and staging lung cancer[J].AmJRespir Crit Care Med,1996,153(1):417-21. [10] Adler LP,CroweJP,Kaisi AL,et al.Evaluation of breast mass and axillary lymph nodes with FDG-PET[J].Radiology,1987,148(54):365-77. [11] Okazumi S,Isono K,Enimoto K,et al.Evaluation of liver tumors using 18F-FDG PET characterization of tumor and assessment of effect oftreatment[J].JNucl Med,1992,33(9):333-9. [12] Magrath I,LitvakJ.Cancer in developing countries:opportunity and challenge[J].JNatl Cancer Inst,1993,85(17):862-73. [13] 王世真,周前.核医学正迈进PET时代[J].国外医学·放射医学核医学分册(Foreign Med·Radiol Nucl Med Sect),1997,21(5/6):247. [14] Higashi K,Veda Y,Yagishita M,et al.FDG PET measurement of proliferative potiential of non-small cell lung cancer [J].JNucl Med,2000,41(1):85-92. [15] 姚树展,张成琪,陈静,等.18F-脱氧葡萄糖结合PET-CT显像诊断肝恶性肿瘤[J].第一军医大学学报,2003,23(11):1214-6.Yao SZ,Zhang CQ,ChenJ,et al.Clinical evaluation of 18F-FDG PET-CT in detecting mail,ant liver tumors [J].JFirst Mil Med Univ/Di YiJun Yi Da Xue Xue Bao,2003,23(11):1214-6. [16] 廖旺军,罗荣成,康世均,等.应用正电子发射断层显像技术评价聚能刀射频治疗恶性肿瘤的近期疗效[J].第一军医大学学报,2002,22(4):376-7.Liao WJ,Luo RC,Kang SJ,et al.Investigation of short-term therapy results for radiofrequency ablation by positron emission tomography[J].JFirst Mil Med Univ/Di YiJun Yi Da Xue Xue Bao,2002,22(4):376-7. [17] Hawkins RA,Hohc H,GlaspyJ,et al.The role of positron emission tomography in oncology and other whole body application [J].Semin Nucl Med,1992,22(8):268-9. [18] Conti PS,Lilien DL,Hawley K,et al.PET and 18F-FDG in positron tomography for oncology:a clinical update [J].Nucl Med Biol,1996,23(12):717-35. [19] 李盂森,李平风,李刚.甲胎蛋白对细胞增殖的调节作用[J].国外医学·肿瘤学分册(ForeignMed·Oncol Sect),2000,27(5):286-8. [20] Crippa F,Gavazzi C,Bozzetti F,et al.The influence of blood glucose levels on 18F-FDG uptake in cancer:a PET study in liver metastases from colorectal carcinomas[J].Tumor,1997,83(4):748-52. |